Daniel Haraf to Neoplasm Recurrence, Local
This is a "connection" page, showing publications Daniel Haraf has written about Neoplasm Recurrence, Local.
Connection Strength
1.288
-
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4):1096-106.
Score: 0.140
-
Reirradiation of recurrent and second primary head and neck malignancies: a comprehensive review. Cancer Treat Rev. 2003 Feb; 29(1):21-30.
Score: 0.121
-
Reirradiation: a potentially curative approach to locally or regionally recurrent head and neck cancer. Curr Opin Oncol. 2002 May; 14(3):330-3.
Score: 0.115
-
Is It Worth It? Consequences of Definitive Head and Neck Reirradiation. Semin Radiat Oncol. 2020 Jul; 30(3):212-217.
Score: 0.101
-
Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer. Semin Oncol. 1997 Feb; 24(1 Suppl 2):S2-68-S2-71.
Score: 0.080
-
Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease. Ann Oncol. 1996 Nov; 7(9):913-8.
Score: 0.078
-
Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):21-9.
Score: 0.076
-
Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma. Oral Oncol. 2013 Mar; 49(3):277-82.
Score: 0.059
-
Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012 Feb; 7(2):376-81.
Score: 0.056
-
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer. 2011 Oct 15; 117(20):4671-8.
Score: 0.054
-
Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. Ann Oncol. 2011 Nov; 22(11):2501-2507.
Score: 0.053
-
Free-flap reconstruction in the doubly irradiated patient population. Plast Reconstr Surg. 2008 Jul; 122(1):125-132.
Score: 0.044
-
Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer. Int J Radiat Oncol Biol Phys. 2007 Mar 01; 67(3):678-84.
Score: 0.040
-
Planned post-chemoradiation neck dissection: significance of radiation dose. Laryngoscope. 2006 Jan; 116(1):33-6.
Score: 0.037
-
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2006 Feb 01; 64(2):382-91.
Score: 0.036
-
Early Dynamics of Circulating Tumor HPV-DNA with Neoadjuvant Chemotherapy and Response-Adapted De-escalation in Human Papillomavirus-Associated Oropharyngeal Cancer. Clin Cancer Res. 2025 Aug 01; 31(15):3150-3159.
Score: 0.036
-
Reirradiation of recurrent head and neck cancers with curative intent. Semin Oncol. 2004 Dec; 31(6):816-21.
Score: 0.034
-
Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma. Br J Cancer. 2022 11; 127(8):1497-1506.
Score: 0.029
-
Oral 5-FU alternatives for the treatment of head and neck cancer. Oncology (Williston Park). 1998 Oct; 12(10 Suppl 7):35-8.
Score: 0.022
-
Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades. Ann Oncol. 2015 Jan; 26(1):198-205.
Score: 0.017
-
Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer. Am J Clin Oncol. 1991 Oct; 14(5):419-26.
Score: 0.014
-
Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. Head Neck Oncol. 2011 Jul 26; 3:31.
Score: 0.014
-
Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer. Cancer J. 2005 Mar-Apr; 11(2):140-6.
Score: 0.009
-
Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol. 2001 Apr 01; 19(7):1961-9.
Score: 0.007
-
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Clin Cancer Res. 1999 Feb; 5(2):291-8.
Score: 0.006
-
The role of paclitaxel in the treatment of head and neck cancer. Semin Oncol. 1995 Oct; 22(5 Suppl 12):8-12.
Score: 0.005
-
Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer. Semin Oncol. 1992 Jun; 19(3 Suppl 9):53-8.
Score: 0.004